Stockscreener 앱 받기
14.59
1.35%
-0.20
시간 외 거래:
13.21
-1.38
-9.46%
전일 마감가:
$14.79
열려 있는:
$14.63
하루 거래량:
455.65K
Relative Volume:
0.50
시가총액:
$906.83M
수익:
$840.00K
순이익/손실:
$-75.20M
주가수익비율:
-9.164
EPS:
-1.5921
순현금흐름:
$-65.69M
1주 성능:
+8.72%
1개월 성능:
+30.62%
6개월 성능:
+152.42%
1년 성능:
+178.97%
1일 변동 폭
$14.42
$14.79
1주일 범위
$13.09
$15.28
52주 변동 폭
$4.19
$17.58
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
명칭
Silence Therapeutics Plc Adr
전화
44-0-20-3457 6900
주소
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
14.59 | 818.57M | 840.00K | -75.20M | -65.69M | -1.5921 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Goldman | Sell |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr 주식(SLN)의 최신 뉴스
Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
What is HC Wainwright's Estimate for SLN Q3 Earnings? - MarketBeat
Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN) - MarketBeat
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com India
Silence Therapeutics closes $201.3M public offering - Investing.com
Silence Therapeutics Director Richard Ian Griffiths Reports Multiple ADS Sales on August 10, 2026 - Kalkine Media
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Yahoo Finance
Silence Therapeutics Announces Pricing of $13.50 Per ADS in Public Offering - Kalkine Media
Form 8K Silence Therapeutics plc For: 12 August By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9%What's Next? - MarketBeat
Silence Therapeutics prices $175M public offering at $13.50 per ADS - Investing.com
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - sharewise.com
Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing - TechStock²
Silence Therapeutics launches $150 million public offering - Investing.com
Silence Therapeutics launches $150 million public offering By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Gap UpStill a Buy? - MarketBeat
Silence Therapeutics Reports Q2 2026 Financial Results in SEC Filing - Kalkine Media
Silence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine Media
Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data - StocksToTrade
Silence Therapeutics (SLN) Rallies Ahead Of Key Phase 2 Data - timothysykes.com
Silence Therapeutics reports positive phase 2 trial results - Investing.com
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Finviz
Why is Silence Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year HighStill a Buy? - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
SLN Q4 2024 Earnings: EPS of $0.2131 Reported; Shares Decline 9.72Tech Earnings Analysis - vinanet.vn
ADAR1 Capital Management LLC Buys 148,514 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Reaches New 12-Month HighTime to Buy? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Stock Price Up 6.9%Here's Why - MarketBeat
SLN stock skyrockets 107% in six months: Here's what you need to know - MSN
Silence Therapeutics (SLN) moves 7.2% higher: Will this strength last? - MSN
ETFs Investing in Silence Therapeutics PLC Sponsored ADR Stocks - TradingView
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know - Yahoo Finance UK
Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance Singapore
Silence Therapeutics (NASDAQ:SLN) Shares Up 10%Here's What Happened - MarketBeat
Form 13D/A Silence Therapeutics Plc For: 8 July By Investing.com - Investing.com South Africa
Silence Therapeutics (SLN) surges 26.0%: Is this an indication of further gains? - MSN
Silence Therapeutics PLC Sponsored ADR Actuals & Estimates (NASDAQ:SLN) - TradingView
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Why is Silence Therapeutics stock surging today? - Investing.com
Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade - Investing.com
Form 8K Silence Therapeutics plc For: 23 June By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Silence Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Silence Therapeutics stock rating at buy - Investing.com
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Sahm
Silence Therapeutics presents divesiran trial data at EHA By Investing.com - Investing.com South Africa
Silence Therapeutics presents divesiran trial data at EHA - Investing.com
Silence Therapeutics (SLN) soars 19.0%: Is further upside left in the stock? - MSN
Silence Therapeutics Plc Adr (SLN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):